Avion gets positive feedback from FDA on two NDAs
Based on the FDA feedback, the company will be moving into Phase II/III on one NDA Program, and into Phase II on the other. In line with the
Akeso has received approval from China’s National Medical Products Administration (NMPA) for gumokimab (AK111), an anti-Interleukin-17 (IL-17) monoclonal antibody, to treat adults with moderate-to-severe plaque psoriasis.
Data from two clinical trials was presented at the American Diabetes Association 74th Scientific Sessions. In the two-year trial, empagliflozin in combination with certain other diabetes therapies showed